Atlas Trials

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

Clinical trial NCT03719690 · COMPLETED

Trial details

NCT number
NCT03719690
Sponsor
Kura Oncology, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HRAS Gene MutationHNSCC
Start date
2019-03-15
Primary completion
2023-05-02
Enrollment
296

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.